Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Gastroenteritis Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Gastroenteritis Overview | 7 | 1 |
| Pipeline Products for Gastroenteritis Comparative Analysis | 8 | 1 |
| Gastroenteritis Therapeutics under Development by Companies | 9 | 1 |
| Gastroenteritis Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Gastroenteritis Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Gastroenteritis Products under Development by Companies | 14 | 1 |
| Gastroenteritis Products under Investigation by Universities/Institutes | 15 | 1 |
| Gastroenteritis Companies Involved in Therapeutics Development | 16 | 4 |
| Nanotherapeutics, Inc. | 16 | 1 |
| RedHill Biopharma Ltd. | 17 | 1 |
| Takeda Pharmaceutical Company Limited | 18 | 1 |
| UMN Pharma Inc. | 19 | 1 |
| Gastroenteritis Therapeutics Assessment | 20 | 7 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 12 |
| Antibodies for Gastroenteritis Drug Profile | 27 | 1 |
| Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders Drug Profile | 28 | 1 |
| norovirus (bivalent) virus like particle vaccine Drug Profile | 29 | 1 |
| ondansetron hydrochloride CR Drug Profile | 30 | 5 |
| TAK-214 Drug Profile | 35 | 2 |
| UMN-2002 Drug Profile | 37 | 1 |
| UMN-2003 Drug Profile | 38 | 1 |
| Gastroenteritis Product Development Milestones | 39 | 9 |
| Featured News &Press Releases | 39 | 1 |
| Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial | 39 | 1 |
| Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 | 39 | 1 |
| Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D | 40 | 1 |
| Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting | 41 | 1 |
| Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis | 42 | 1 |
| Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support | 43 | 1 |
| Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis | 44 | 1 |
| Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness | 45 | 1 |
| Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting | 46 | 2 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |